{"id":3236,"date":"2016-11-28T00:00:00","date_gmt":"2016-11-28T00:00:00","guid":{"rendered":"https:\/\/abes.org.br\/?p=3236"},"modified":"2016-11-28T00:00:00","modified_gmt":"2016-11-28T00:00:00","slug":"theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil","status":"publish","type":"post","link":"https:\/\/abes.org.br\/en\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\/","title":{"rendered":"TheraSkin uses IBM Watson to develop new drugs and dermocosmetics in Brazil"},"content":{"rendered":"<div style=\"text-align: justify;\">\n\t&nbsp;<\/div>\n<div style=\"text-align: center;\">\n\t<br \/>\n\t<img decoding=\"async\" alt=\"\" src=\"\/wp-content\/uploads\/anterior\/Imagens\/0000000theraskin.jpg\" style=\"width: 320px; height: 156px;\" \/><br \/>\n\tPharmaceuticals is the first in Latin America to use IBM cognitive computing in skin care product research<\/div>\n<div style=\"text-align: justify;\">\n\t&nbsp;<br \/>\n\tTheraSkin, a specialized Brazilian pharmaceutical company and a reference in dermatology throughout the country, is the first company in Latin America to use the IBM Watson for Drug Discovery solution. The use of the cognitive computing platform aims to help the RD&amp;I area in the development of products that provide the market with increasingly efficient, innovative solutions capable of meeting the wishes of the medical community and its consumers.<br \/>\n\t&nbsp;<br \/>\n\tWatson for Drug Discovery is an IBM cloud-hosted solution that leverages cognitive computing to deliver dynamic visualizations and rankings of clinical research. This analysis is based on evidence extracted from the most recent scientific articles, medical journals, books and patent records. Artificial intelligence technology helps scientists identify relationships between genes, proteins and drugs related to the diseases under study, streamlining the process of new scientific discoveries.<br \/>\n\t&nbsp;<br \/>\n\t\u201cWith the integration of Watson into our RD&amp;I team, through its Cognitive Intelligence, we will be able to evaluate thousands of documents and literature in a time interval that would be impossible in traditional means, as well as generate new research hypotheses with great capacity. preditiv\u201d, evaluates TheraSkin Research, Development and Innovation manager, Deli Oliveira.<br \/>\n\t&nbsp;<br \/>\n\tBrazil has a very timely and challenging scenario in terms of innovation in skin care products, especially because of the great mix of ethnicities present in the country and also because of its tropical profile. \u201cIn just 2 months of using Watson for Drug Discovery, we have already shown that it brings together a large amount of knowledge that can be absorbed in the form of new ideas to overcome these challenges. Our intention is also to support many projects that are in their initial phase, consolidate others in progress and make possible differentiated and agile paths in the development of products far from the obvious, something that in Research can be a great business opportunity for companies\u201d , completes Oliveira.<br \/>\n\t&nbsp;<br \/>\n\tThe Watson for Drug Discovery platform is part of the services portfolio of the IBM Watson Health global business unit, which was launched in April 2015, and has the proposal to improve patient care through projects with cognitive computing. \u201cIn the health area, cognitive computing supports professionals \u2013 whether doctors, scientists or companies \u2013 so that their decisions are increasingly based on scientific data and, ultimately, more accurate\u201d, emphasizes the leader of the IBM Watson Health unit in the Brazil, Eduardo Cipriani.<\/div>\n<p>\n&nbsp;<\/p>","protected":false},"excerpt":{"rendered":"<p>&nbsp; Farmac&ecirc;utica &eacute; a primeira na Am&eacute;rica Latina a usar computa&ccedil;&atilde;o cognitiva da IBM em pesquisa de&nbsp; produtos para cuidados com a pele &nbsp; A TheraSkin, uma ind&uacute;stria farmac&ecirc;utica brasileira especializada e refer&ecirc;ncia em dermatologia em todo o Pa&iacute;s, &eacute; a primeira empresa da Am&eacute;rica Latina a utilizar a solu&ccedil;&atilde;o IBM Watson for Drug Discovery. [&hellip;]<\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"_et_pb_use_builder":"","_et_pb_old_content":"","_et_gb_content_width":"","footnotes":""},"categories":[19],"tags":[],"class_list":["post-3236","post","type-post","status-publish","format-standard","hentry","category-ultimas-noticias"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.3 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>TheraSkin utiliza IBM Watson para desenvolvimento de novos medicamentos e dermocosm\u00e9ticos no Brasil - ABES<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/abes.org.br\/en\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TheraSkin utiliza IBM Watson para desenvolvimento de novos medicamentos e dermocosm\u00e9ticos no Brasil - ABES\" \/>\n<meta property=\"og:description\" content=\"&nbsp; Farmac&ecirc;utica &eacute; a primeira na Am&eacute;rica Latina a usar computa&ccedil;&atilde;o cognitiva da IBM em pesquisa de&nbsp; produtos para cuidados com a pele &nbsp; A TheraSkin, uma ind&uacute;stria farmac&ecirc;utica brasileira especializada e refer&ecirc;ncia em dermatologia em todo o Pa&iacute;s, &eacute; a primeira empresa da Am&eacute;rica Latina a utilizar a solu&ccedil;&atilde;o IBM Watson for Drug Discovery. [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/abes.org.br\/en\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\/\" \/>\n<meta property=\"og:site_name\" content=\"ABES\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/ABES.software\" \/>\n<meta property=\"article:published_time\" content=\"2016-11-28T00:00:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/abes.org.br\/wp-content\/uploads\/2021\/01\/logo_abes_marca_tagline_horizontal_colorido_rgb.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3509\" \/>\n\t<meta property=\"og:image:height\" content=\"2482\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"prima-dev\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ABES_SOFTWARE\" \/>\n<meta name=\"twitter:site\" content=\"@ABES_SOFTWARE\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"prima-dev\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/abes.org.br\\\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/abes.org.br\\\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\\\/\"},\"author\":{\"name\":\"prima-dev\",\"@id\":\"https:\\\/\\\/abes.org.br\\\/#\\\/schema\\\/person\\\/1bad6bff859e7d56ec5664b01968e27e\"},\"headline\":\"TheraSkin utiliza IBM Watson para desenvolvimento de novos medicamentos e dermocosm\u00e9ticos no Brasil\",\"datePublished\":\"2016-11-28T00:00:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/abes.org.br\\\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\\\/\"},\"wordCount\":603,\"publisher\":{\"@id\":\"https:\\\/\\\/abes.org.br\\\/#organization\"},\"articleSection\":[\"\u00daltimas not\u00edcias\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/abes.org.br\\\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\\\/\",\"url\":\"https:\\\/\\\/abes.org.br\\\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\\\/\",\"name\":\"TheraSkin utiliza IBM Watson para desenvolvimento de novos medicamentos e dermocosm\u00e9ticos no Brasil - ABES\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/abes.org.br\\\/#website\"},\"datePublished\":\"2016-11-28T00:00:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/abes.org.br\\\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/abes.org.br\\\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/abes.org.br\\\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"In\u00edcio\",\"item\":\"https:\\\/\\\/abes.org.br\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TheraSkin utiliza IBM Watson para desenvolvimento de novos medicamentos e dermocosm\u00e9ticos no Brasil\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/abes.org.br\\\/#website\",\"url\":\"https:\\\/\\\/abes.org.br\\\/\",\"name\":\"ABES\",\"description\":\"Associa\u00e7\u00e3o Brasileira das Empresas de Software\",\"publisher\":{\"@id\":\"https:\\\/\\\/abes.org.br\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/abes.org.br\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/abes.org.br\\\/#organization\",\"name\":\"Associa\u00e7\u00e3o Brasileira das Empresas de Software\",\"url\":\"https:\\\/\\\/abes.org.br\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/abes.org.br\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/abes.org.br\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/logo_abes_marca_d_tagline_horizontal_verde-amarelo_cmyk.png\",\"contentUrl\":\"https:\\\/\\\/abes.org.br\\\/wp-content\\\/uploads\\\/2020\\\/09\\\/logo_abes_marca_d_tagline_horizontal_verde-amarelo_cmyk.png\",\"width\":324,\"height\":70,\"caption\":\"Associa\u00e7\u00e3o Brasileira das Empresas de Software\"},\"image\":{\"@id\":\"https:\\\/\\\/abes.org.br\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/ABES.software\",\"https:\\\/\\\/x.com\\\/ABES_SOFTWARE\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/abes-software\\\/\",\"https:\\\/\\\/www.instagram.com\\\/abes_software\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/abes.org.br\\\/#\\\/schema\\\/person\\\/1bad6bff859e7d56ec5664b01968e27e\",\"name\":\"prima-dev\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/039c6325210cecd393c57645bc755f7d13deed578fddf4dbfa87bc05dcbcfa4b?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/039c6325210cecd393c57645bc755f7d13deed578fddf4dbfa87bc05dcbcfa4b?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/039c6325210cecd393c57645bc755f7d13deed578fddf4dbfa87bc05dcbcfa4b?s=96&d=mm&r=g\",\"caption\":\"prima-dev\"},\"url\":\"https:\\\/\\\/abes.org.br\\\/en\\\/author\\\/prima-dev\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TheraSkin utiliza IBM Watson para desenvolvimento de novos medicamentos e dermocosm\u00e9ticos no Brasil - ABES","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/abes.org.br\/en\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\/","og_locale":"en_US","og_type":"article","og_title":"TheraSkin utiliza IBM Watson para desenvolvimento de novos medicamentos e dermocosm\u00e9ticos no Brasil - ABES","og_description":"&nbsp; Farmac&ecirc;utica &eacute; a primeira na Am&eacute;rica Latina a usar computa&ccedil;&atilde;o cognitiva da IBM em pesquisa de&nbsp; produtos para cuidados com a pele &nbsp; A TheraSkin, uma ind&uacute;stria farmac&ecirc;utica brasileira especializada e refer&ecirc;ncia em dermatologia em todo o Pa&iacute;s, &eacute; a primeira empresa da Am&eacute;rica Latina a utilizar a solu&ccedil;&atilde;o IBM Watson for Drug Discovery. [&hellip;]","og_url":"https:\/\/abes.org.br\/en\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\/","og_site_name":"ABES","article_publisher":"https:\/\/www.facebook.com\/ABES.software","article_published_time":"2016-11-28T00:00:00+00:00","og_image":[{"width":3509,"height":2482,"url":"https:\/\/abes.org.br\/wp-content\/uploads\/2021\/01\/logo_abes_marca_tagline_horizontal_colorido_rgb.png","type":"image\/png"}],"author":"prima-dev","twitter_card":"summary_large_image","twitter_creator":"@ABES_SOFTWARE","twitter_site":"@ABES_SOFTWARE","twitter_misc":{"Written by":"prima-dev","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/abes.org.br\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\/#article","isPartOf":{"@id":"https:\/\/abes.org.br\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\/"},"author":{"name":"prima-dev","@id":"https:\/\/abes.org.br\/#\/schema\/person\/1bad6bff859e7d56ec5664b01968e27e"},"headline":"TheraSkin utiliza IBM Watson para desenvolvimento de novos medicamentos e dermocosm\u00e9ticos no Brasil","datePublished":"2016-11-28T00:00:00+00:00","mainEntityOfPage":{"@id":"https:\/\/abes.org.br\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\/"},"wordCount":603,"publisher":{"@id":"https:\/\/abes.org.br\/#organization"},"articleSection":["\u00daltimas not\u00edcias"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/abes.org.br\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\/","url":"https:\/\/abes.org.br\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\/","name":"TheraSkin utiliza IBM Watson para desenvolvimento de novos medicamentos e dermocosm\u00e9ticos no Brasil - ABES","isPartOf":{"@id":"https:\/\/abes.org.br\/#website"},"datePublished":"2016-11-28T00:00:00+00:00","breadcrumb":{"@id":"https:\/\/abes.org.br\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/abes.org.br\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/abes.org.br\/theraskin-utiliza-ibm-watson-para-desenvolvimento-de-novos-medicamentos-e-dermocosmeticos-no-brasil\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"In\u00edcio","item":"https:\/\/abes.org.br\/"},{"@type":"ListItem","position":2,"name":"TheraSkin utiliza IBM Watson para desenvolvimento de novos medicamentos e dermocosm\u00e9ticos no Brasil"}]},{"@type":"WebSite","@id":"https:\/\/abes.org.br\/#website","url":"https:\/\/abes.org.br\/","name":"ABES","description":"Brazilian Association of Software Companies","publisher":{"@id":"https:\/\/abes.org.br\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/abes.org.br\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/abes.org.br\/#organization","name":"Brazilian Association of Software Companies","url":"https:\/\/abes.org.br\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/abes.org.br\/#\/schema\/logo\/image\/","url":"https:\/\/abes.org.br\/wp-content\/uploads\/2020\/09\/logo_abes_marca_d_tagline_horizontal_verde-amarelo_cmyk.png","contentUrl":"https:\/\/abes.org.br\/wp-content\/uploads\/2020\/09\/logo_abes_marca_d_tagline_horizontal_verde-amarelo_cmyk.png","width":324,"height":70,"caption":"Associa\u00e7\u00e3o Brasileira das Empresas de Software"},"image":{"@id":"https:\/\/abes.org.br\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/ABES.software","https:\/\/x.com\/ABES_SOFTWARE","https:\/\/www.linkedin.com\/company\/abes-software\/","https:\/\/www.instagram.com\/abes_software\/"]},{"@type":"Person","@id":"https:\/\/abes.org.br\/#\/schema\/person\/1bad6bff859e7d56ec5664b01968e27e","name":"prima-dev","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/039c6325210cecd393c57645bc755f7d13deed578fddf4dbfa87bc05dcbcfa4b?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/039c6325210cecd393c57645bc755f7d13deed578fddf4dbfa87bc05dcbcfa4b?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/039c6325210cecd393c57645bc755f7d13deed578fddf4dbfa87bc05dcbcfa4b?s=96&d=mm&r=g","caption":"prima-dev"},"url":"https:\/\/abes.org.br\/en\/author\/prima-dev\/"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-25 22:53:16","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"category","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/abes.org.br\/en\/wp-json\/wp\/v2\/posts\/3236","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/abes.org.br\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/abes.org.br\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/abes.org.br\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/abes.org.br\/en\/wp-json\/wp\/v2\/comments?post=3236"}],"version-history":[{"count":0,"href":"https:\/\/abes.org.br\/en\/wp-json\/wp\/v2\/posts\/3236\/revisions"}],"wp:attachment":[{"href":"https:\/\/abes.org.br\/en\/wp-json\/wp\/v2\/media?parent=3236"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/abes.org.br\/en\/wp-json\/wp\/v2\/categories?post=3236"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/abes.org.br\/en\/wp-json\/wp\/v2\/tags?post=3236"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}